Lotus Eye Hospital and Institute Limited (LOTUSEYE) fundamentals
Lotus Eye Hospital and Institute Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as LOTUSEYE (ISIN INE947I01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Lotus Eye Hospital and Institute Limited does
Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company is engaged in the field of ophthalmology (eye) and its related operations. It resolves a range of eye problems, such as refractive, cataract, cornea infections, ocular prosthesis, orbit and oculoplasty, glaucoma, keratoconus, computer vision syndrome, neuro ophthalmology, retinal disease/diabetic eye care, UVEA and ocular inflammation, zyoptix-ultimate, and binocular vision. The Company provides various treatments, suchas ReLEx SMILE, Touchfree Laser, Lasik Eye Surgery, Epi-LASIK, Intralase, Supracor, Robotic Femto Laser Cataract Surgery (LRCS), Phacoemulsification, Paediatric Eye Care and Squint Surgery, and Micro Incision Cataract Surgery (MICS). The Company operates in various locations, such as Sitra, Coimbatore; RS Puram, Coimbatore; Salem; Tirupur; Mettupalayam; Kochi; Mulanthuruthy; Saravanampatty, and Karur.
Valuation and market data
| Last close | ₹113.50 |
|---|---|
| Market capitalisation | ₹233 crore |
| Enterprise value | ₹233 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.89 |
| Price to sales (TTM) | 3.99 |
| Book value per share | ₹29.19 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Fri Jul 11 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹55 crore | ₹-0 crore | ₹0 crore | 0.00 |
| Mar 2025 | ₹51 crore | ₹1 crore | ₹1 crore | 0.36 |
| Mar 2024 | ₹50 crore | ₹4 crore | ₹3 crore | 1.40 |
| Mar 2023 | ₹48 crore | ₹6 crore | ₹4 crore | 1.96 |
| Mar 2022 | ₹40 crore | ₹4 crore | ₹3 crore | 1.44 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 40.1% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 59.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.